Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 12, 1997, Pages 3955-3963

  Campos, Hannia ^a   Walsh, Brian W ^b   Judge, Helena ^a   Sacks, Frank M ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030865399     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.12.3955     Document Type: Article

References (42)

1. Psaty BM, Heckbert SR, Atkins D, et al. 1993 A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 153:1421-1427.
2. Grodstein F, Stampfer MJ, Manson JE, et al. 1996 Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:453-461.
3. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1196-1204.
4. The Writing Group for the PEPI Trial. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trail. JAMA. 273:199-208.
5. Granfone A, Campos H, McNamara JR, et al. 1992 Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 41:1193-1198.
6. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. 1993 Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism. 42:1153-1158.
7. Griffin B, Farish E, Walsh D, et al. 1993 Response of plasma low density lipoprotein subtractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol (Oxf). 39:463-468.
8. van der Mooren MJ, de Graff J, Demacker PN, de Haan AF. 1994 Changes in the low-density lipoprotein profile during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism. 43:799-802.
9. Campos H, Genest J, Blijlevens E, et al. 1992 Low density lipoprotein particle size and coronary artery disease. Arteriosclerosis. 12:187-195.
10. Coresh J, Kwiterovich Jr PO, Smith HH, Bachorik PS. 1993 Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 34:1687-1697.
11. Stampfer MJ, Krauss RM, Ma J, et al. 1996 A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:882-888.
12. Gardner CD, Fortmann SP, Krauss RM. 1996 Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:875-881.
13. Camejo G, Hurt-Camejo E, Bondjers G. 1990 Effect of proteoglycans on lipoprotein-cell interactions: possible contributions to atherogenesis. Curr Opin Lipidol. 1:431-436.
14. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. 1996 Differences in receptor binding of low density lipoprotein subfractions. Arterioscler Thromb Vasc Biol. 16:769-801.
15. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. 1991 Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosclerosis. 11:298-306.
16. Campos H, Blijlevens E, McNamara JR, et al. 1992 Low density lipoprotein particle size distribution: results from the Framingham Offspring Study. Arterioscler. Thromb. 12:1410-1419.
17. Krauss RM. 1994 Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 5:339-349.
18. Krauss RM, Blanche PJ. 1992 Detection and quantitation of LDL subfractions. Curr Opin Lipidol. 3:377-383.
19. Lapidus L, Bengtsoon C, Lindquist O, Sigurdsson JA, Rybo E. 1985 Triglycerides-main lipid risk factor for cardiovascular disease in women? Acta Med Scand. 217:481-489.
20. Criqui MH, Heiss G, Cohn R, et al. 1993 Plasma triglyceride and mortality from coronary heart disease. N Engl J Med. 328:1220-1225.
21. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepard J. 1984 Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest. 74:2178-2192.
22. Tarami R, Mabuchi H, Ueda K, et al. 1981 Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 64:1174-1184.
23. Bersot TP, Innerarity TL, Mahley RW, Havel RJ. 1983 Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. J Clin Invest. 72:1024-1033.
24. Sacks FM, Breslow JL. 1987 Very low density lipoproteins stumulate cholesteryl ester formation in U937 macrophages. Heterogeneity and biologic variation among normal humans. Arteriosclerosis. 7:35-46.
25. Tall A, Granot E, Brocia R, et al. 1987 Accelerated transfer of cholesteryl esters in dyslipidemic plasma: role of cholesteryl ester transfer protein. J Clin Invest. 79:1217-1225.
26. Walzern RL, Watkins S, Frankel EN, Hansen RJ, German JB. 1995 Older plasma lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid and oxidation theories of atherosclerotic cardiovascular disease. Proc Natl Acad Sci USA. 92:7460-7464.
27. Lipid Metabolism Branch, Division of Heart, and Vascular Diseases, National Heart, Lung, and Blood Institute. 1980 The Lipid Research Clinics population studies data book. Bethesda: Lipid Metabolism Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, NIH; publication 80-1527.
28. Egusa G, Brady DW, Grundy SM, Howard BV. 1983 Isopropanol precipitation method for metabolic studies of very low density lipoprotein apolipoprotein B. J Lipid Res. 24:1261-1267.
29. Windler EET, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. 1980 The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem. 255:10464-10471.
30. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. 1989 Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 84:802-810.
31. Colvin Jr PLJ. 1996 Estrogen increases low-density lipoprotein receptor-independent catabolism of apolipoprotein B in hyperlipidemic rabbits. Metabolism. 45:889-896.
32. Srivastava RAK, Baumann D, Schonfeld G. 1993 In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem. 216:527-538.
33. Teng B, Sniderman A, Kauss RM, Kwiterovich ROJ, Milne RW, Marcel IL. 1985 Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. J Biol Chem. 260:5067-5072.
34. McNamara JR, Small DM, Li Z, Schaefer EJ. 1996 Differences in LDL subspecies involve alterations in lipid composition and conformation changes in apolipoprotein B. J Lipid Res. 37:1924-1935.
35. Rudel LL, Parks JS, Johnson FL, Babiak J. 1986 Low density lipoproteins in atherosclerosis. J Lipid Res. 27:465-474.
36. 2 cholesterol in normolipidemic with coronary artery disease. Arterioscler Thromb Vasc Biol. 15:1043-1048.
37. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. 1990 Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 265:10771-10779.
38. Ginsberg HN, Le NA, Goldberg IJ, et al. 1986 Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 78:1287-1295.
39. Glueck CJ, Fallat RW, Scheel D. 1975 Effects of estrogenic compounds on triglyceride kinetics. Metabolism. 24:537-345.
40. Kissebah AH. 1973 Mechanism of hypertriglyceridaemia associated with contraceptive steroids. Horm Res. 5:184-190.
41. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HBJ, Levy RI. 1983 The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab. 57:262-267.
42. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. 1990 Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. J Clin Invest. 85:804-811.